Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded Arcturus Therapeutics from “sell” to “hold,” while Citigroup raised its rating to “buy” and increased its price target to $20. Overall, analysts have a “Moderate Buy” consensus with an average target of $22.43.
• ARCT opened at $13.85, above its 50-day moving average of $11.21 and 200-day moving average of $8.83. The stock has traded between $5.50 and $24.17 over the past year and carries a market capitalization of approximately $393.6 million.
• The biotechnology company reported a quarterly loss of $0.84 per share, beating estimates for a $1.00 loss, though revenue of $2.96 million fell short of forecasts. Institutional investors own approximately 94.54% of the stock.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report released on Saturday, Wall Street Zen reports.

ARCT has been the subject of several other reports. Citigroup upgraded Arcturus Therapeutics from a "neutral" rating to a "buy" rating and upped their target price for the company from $8.00 to $20.00 in a report on Thursday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Arcturus Therapeutics in a report on Friday, July 17th. Cantor Fitzgerald reissued an "overweight" rating on shares of Arcturus Therapeutics in a report on Thursday. Roth Capital restated a "buy" rating and set a $41.00 price objective on shares of Arcturus Therapeutics in a research report on Wednesday, September 2nd. Finally, BTIG Research dropped their price target on shares of Arcturus Therapeutics from $23.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Arcturus Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $22.43.

Arcturus Therapeutics Stock Performance

ARCT opened at $13.85 on Friday. The company has a fifty day moving average of $11.21 and a two-hundred day moving average of $8.83. The stock has a market capitalization of $393.62 million, a price-to-earnings ratio of -4.18 and a beta of 2.48. Arcturus Therapeutics has a fifty-two week low of $5.50 and a fifty-two week high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its earnings results on Friday, August 7th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.00) by $0.16. The firm had revenue of $2.96 million for the quarter, compared to analyst estimates of $3.11 million. Arcturus Therapeutics had a negative return on equity of 46.54% and a negative net margin of 317.62%. On average, equities research analysts forecast that Arcturus Therapeutics will post -3.48 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ARCT. Two Sigma Securities LLC acquired a new stake in Arcturus Therapeutics during the second quarter worth approximately $80,000. ADAR1 Capital Management LLC purchased a new position in shares of Arcturus Therapeutics in the 1st quarter valued at $116,000. Diversify Wealth Management LLC purchased a new position in shares of Arcturus Therapeutics in the 1st quarter valued at $133,000. Diversify Advisory Services LLC acquired a new stake in Arcturus Therapeutics during the 2nd quarter worth $91,000. Finally, Castleview Partners LLC acquired a new stake in Arcturus Therapeutics during the 1st quarter worth $130,000. 94.54% of the stock is currently owned by hedge funds and other institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a biotechnology company focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. The company's platform includes LUNAR, a lipid-mediated delivery system designed to transport nucleic acid medicines into targeted cells, and STARR, a self-amplifying mRNA technology intended to produce therapeutic proteins from relatively small doses of RNA.

Arcturus is developing RNA-based candidates for rare diseases, infectious diseases, and other conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.